A Phase 4 interventional study of Angiotensin-II in Vasodilatory Shock, sponsored by Northwell Health. Enrolling by invitation at 2 sites in United States. Open to participants aged 0 Days to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Northwell Health · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Shock with a site in United States — 12 open to participants now, 18 under way, 1 of them phase 3. Shock · United States.
Among the 83 studies in Shock with a site in United States, this one is the 35th largest by planned enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2025, is one of 9 in phase 4, reaches primary completion later than 16 of the 17 other live ones, and was the 79th registered.
487 studies on the registry are indexed under Shock; 107 are open to participants now.
Browse Shock studies →12 of the 83 studies in Shock with a site in United States are open now. Recruiting first, the newest first:
University of California, Davis · Sites in United States
Ages up to 28 days
Kingman Regional Medical Center · Sites in United States
Ages 18+
Jason Sperry · Sites in United States
Ages 18+
Montefiore Medical Center · Sites in United States
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Shock studies recruiting now, 52 (76%) set no upper age limit and 11 (16%) stop at 75 or younger; 9 take children under 18; 4 take healthy volunteers.
This study: 0 Days to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 10 · Phase 4 9
First in 2001; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 100 across 229 interventional studies indexed under Shock.
Median enrollment 100 across the 49 interventional studies, 106 across the 34 observational. Of the 58 that completed or were terminated, 21 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 83 have an industry lead sponsor. The 10 most frequent:
Northwell Health is the lead sponsor of 476 studies on the registry; 106 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 23 (48%) have results posted.
Northwell Health has 3 studies filed under Shock — fewer than ten, so there is no comparison to draw.
6 of the studies in Shock with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06895213Mayo ClinicEvaluation of Plasma Renin Concentrations in Cardiac Surgery | 2026-12 |
| NCT05267886Ottawa Heart Institute Research CorporationCAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock | 2026-12 |
| NCT07425587Bluejay Diagnostics, Inc.Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study | 2026-12-30 |
| NCT06654895Bluejay Diagnostics, Inc.Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study | 2026-12-31 |
| NCT06713668Vanderbilt University Medical CenterAugmented Pacing for Shock in the Cardiac Intensive Care Unit | 2027-04-22 |
Add all 6 to your calendar (.ics) → With an account.
Among the 83 studies in Shock with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine the safety and efficacy of Angiotensin-II in the treatment of pediatric patients in fluid refractory vasodilatory shock. The main questions it aims to answer are:
To establish the safety and tolerability of Angiotensin-II in pediatric patients Participants will receive Angiotensin-II in addition to standard of care therapy for vasodilatory shock.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients enrolled in the study who meet inclusion criteria will receive Angiotensin-II per the titration protocol.
Drug: Angiotensin-II
Angiotensin-II will be given per the titration protocol.
Percentage of patients who have improvement in mean arterial pressure or reduction in sum norepinephrine equivalent at Hour 2 after the start of Synthetic Angiotensin-II
Percentage (%) of patients who have improvement in mean arterial pressure (MAP, mmHg) or reduction in sum norepinephrine (NE) equivalent at Hour 2 after the start of Synthetic Angiotensin-II
Time frame: From enrollment to Hour 2
Change in MAP
Change in mean arterial pressure (mmHg) from baseline to 24 hours
Time frame: From enrollment to 24 hours
Change in systolic blood pressure
Change in systolic blood pressure (mmHg) from baseline to 24 hours
Time frame: From enrollment to 24 hours
Change in diastolic blood pressure
Change in diastolic blood pressure (mmHg) from baseline to 24 hours
Time frame: From enrollment to 24 hours
Change in concentration of serum lactate
Change in concentration of serum lactate (mmol/L) from baseline to 2 hours
Time frame: From enrollment to 24 hours
Change in pSOFA score
Change in pSOFA score from screening to 24 hours (%)
Time frame: From enrollment to 24 hours
Change in PRSIM-III score
Change in PRSIM-III score from screening to 24 hours (%)
Time frame: From enrollment to 24 hours
Change in total neutrophil count
Change in total neutrophil count (cells/µL) from the start of Synthetic Angiotensin-II to 24 hours
Time frame: From enrollment to 24 hours
Change in renal resistive index (%)
Change in renal resistive index (%) from the start of Synthetic Angiotensin-II to 24 hours after the start of Synthetic Angiotensin-II
Time frame: From enrollment to 24 hours
Change in tissue oxygenation over 2 hours
Change in tissue oxygenation as defined by peripheral oxygen saturation (%) from baseline to 2 hours
Time frame: From enrollment to Hour 2
Change in tissue oxygenation over 24 hours
Change in tissue oxygenation as defined by peripheral oxygen saturation (%) from baseline to 24 hours
Time frame: From enrollment to Hour 24
Change in heart rate
Change in heart rate (beats per minute) from baseline to 2 hours
Time frame: From enrollment to Hour 2
Change in sum norepinephrine equivalent dose over 24 hours
Change in sum norepinephrine equivalent dose (μg/kg/min) from baseline to 24 hours
Time frame: From enrollment to 24 hours
28-day all-cause mortality
28-day all-cause mortality (%)
Time frame: From enrollment to Day 28
Number of ventilator days
Number of ventilator days
Time frame: From enrollment to Day 28
Ventilator free days
Number of ventilator free days
Time frame: From enrollment to Day 28
Days on vasoactive support
Number of days on vasoactive support
Time frame: From enrollment to Day 28
Change in T cell cell count
Change in T cell cell count (cells/µL)
Time frame: From enrollment to Day 28
Change in in serum cytokine levels
Change in in serum cytokine levels over time (pg/dL)
Time frame: From enrollment to Day 28
Change in renal resistive index (%) over time
Change in renal resistive index (%) over time
Time frame: From enrollment to 28 days
Change in renal blood flow over time
Change in renal blood flow (mL/min) over time
Time frame: From enrollment to 28 days
Change in power doppler by point of care ultrasound assessment
Change in power doppler by point of care ultrasound assessment (AU)
Time frame: From enrollment to 28 days
Plan to share: No
Started Oct 2025 (actual). Primary completion is estimated for Jun 2030, 56 months after the start.
Start moved once since we started tracking on Sep 25, 2026: Sep 2025 → Oct 2025, on Oct 23, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Angiotensin II